🚨Rethinking Blood Eosinophils (BEC) for Assessing #ICS Response in #COPD: A Post-Hoc Analysis from #FLAME. - BEC change during ICS treatment predicts treatment response to ICS in COPD. - BEC measured on ICS treatment misclassify 9% of patients. @journal_CHEST .@ManchesterBRC

RT @ProfJDChalmers: The new European Respiratory Journal impact factor is 21. Ranked #2 across all resp journals. Thank you to the incredib….

RT @ERSpublications: We are pleased to announced our new 2024 Journal Impact Factors:. European Respiratory Journal, 21.0 (Q1).European Res….

RT @EuroRespSoc: 📅ERS President Prof. Silke Ryan has opened the ‘ERS Presidential Summit on Prevention: Improving Respiratory Health in Eur….

👉 Ex-smokers with high BEC (≥200) do benefit from LABA+ICS.🚭 But current smokers? Minimal ICS response. 📊 Smoking status modifies ICS efficacy. @JensUlrikJensen .@victoriachgr .@ManchesterBRC .@UoM_DIIIRM

🔥 Our new analysis from the #FLAMEtrial - just published @ThoraxBMJ:.📉 Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: Insights from the FLAME trial.

It was a great pleasure to speak about career pathways in airway diseases at the @RSMResp #CareersDay. Great event! Thank you @RSMResp and @DrSachinAnanth for the invitation!.

RT @EuroRespSoc: ERS is delighted to announce the 2025 Fellows of ERS (FERS) awardees ⭐ . The FERS award recognises outstanding contributio….

🌟Delighted and honoured to be selected as a Fellow of the @EuroRespSoc (#FERS)!. ERS has supported me throughout my clinical, research, and professional journey. Grateful for the recognition—and excited to give back. Congrats to all 2025 Fellows!.🔗

🚨 Submit your articles at our Research Topic @Frontiers in Allergy."Biologics for Airway Diseases: From Bench to Bedside".🔬🧬💉. Topic Editors: Lena Uller, Dina Visca, @ngpdoc, @MathioudakisAG . 🗓️ Submissions now open!.🔗

RT @DrSachinAnanth: JUST PUBLISHED: our article on the highlights of @EuroRespSoc Assembly 5 at ERS 2024. Makes me very excited for #ERSCon….

RT @DrSachinAnanth: Pleasure to speak at the @RespirEffect Summit today about our work on viruses in asthma. Thank you to the organisers fo….

@SebastianBate @MatthewSperrin @VirtueOfNothing @ManchesterBRC @UoM_DIIIRM.

🌟We hope that ICS‑RECODE will contribute to more informed, personalized treatment decisions in COPD care. Stay tuned for updates as we move forward with this research.

🤝 Multistakeholder collaboration is central—integrating input from clinicians, researchers, and patient representatives to ensure real‑world relevance and drive evidence‑based COPD management. #PatientInvolvement #COPDResearch.

🔍 Focused on blood eosinophils as a key biomarker, ICS‑RECODE will evaluate which patients reap maximum benefits from ICS—balancing improved outcomes against potential risks like pneumonia. #Biomarkers #RespiratoryResearch.

🛠️Using a two‑stage meta‑analysis approach aligned with Cochrane and GRADE guidelines, we will rigorously re‑evaluate both efficacy and safety outcomes of ICS. This method helps ensure robust assessment of treatment×covariate interactions.

🚀 Introducing the ICS‑RECODE research programme: An IPD meta‑analysis aimed at identifying predictors of response to inhaled corticosteroids (#ICS) in #COPD. Our work builds on data from 22 RCTs with over 50,000 participants.

RT @RSMResp: Don't miss our @RoySocMed Respiratory Careers Day on 12th May. Topics include different subspecialties, research/leadership/te….

RT @med_indonews: Irish Thoracic Society Annual Scientific Meeting:. Altering the trajectory of COPD. #COPD @MathioudakisAG @irishthoracicS….

RT @MarkusFally: